Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
Portfolio Pulse from
Rhythm Pharmaceuticals reported its third quarter 2024 financial results, highlighting a net revenue of $33.3 million from global sales of IMCIVREE. Additionally, adult patients with acquired hypothalamic obesity showed a mean BMI reduction of 12.8% after three months of setmelanotide therapy in a French early-access program.
November 05, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals reported $33.3 million in Q3 2024 revenue from IMCIVREE sales. The drug showed promising results in reducing BMI by 12.8% in a French early-access program for hypothalamic obesity.
The financial results indicate strong sales performance of IMCIVREE, which is a positive indicator for Rhythm Pharmaceuticals. The promising clinical results in the French program could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100